APOE and Alzheimer disease: In mouse models of AD-relevant amyloid deposition, direct LXR/RXR agonists increase lipidated apoE, improve memory performance, and can lower amyloid load, suggesting that increasing the levels of functional, lipid-carrying apoE is of therapeutic benefit [70–72].